Parallel Advisors’s Thermo Fisher Scientific TMO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $18.9M | Buy |
37,694
+643
| +2% | +$309K | 0.29% | 57 |
|
|
2026
Q1 | $18.2M | Buy |
37,051
+1,157
| +3% | +$628K | 0.33% | 55 |
|
|
2025
Q4 | $20.8M | Buy |
35,894
+108
| +0.3% | +$61.1K | 0.38% | 47 |
|
|
2025
Q3 | $17.4M | Buy |
35,786
+591
| +2% | +$275K | 0.32% | 51 |
|
|
2025
Q2 | $14.3M | Sell |
35,195
-1,263
| -3% | -$528K | 0.29% | 59 |
|
|
2025
Q1 | $18.1M | Buy |
36,458
+3,114
| +9% | +$1.69M | 0.41% | 41 |
|
|
2024
Q4 | $17.3M | Buy |
33,344
+8
| +0% | +$4.4K | 0.39% | 45 |
|
|
2024
Q3 | $20.6M | Buy |
33,336
+1,272
| +4% | +$753K | 0.48% | 35 |
|
|
2024
Q2 | $17.7M | Buy |
32,064
+750
| +2% | +$430K | 0.45% | 37 |
|
|
2024
Q1 | $18.2M | Buy |
31,314
+1,577
| +5% | +$885K | 0.49% | 33 |
|
|
2023
Q4 | $15.8M | Sell |
29,737
-158
| -0.5% | -$76.5K | 0.47% | 43 |
|
|
2023
Q3 | $15.1M | Buy |
29,895
+298
| +1% | +$159K | 0.5% | 38 |
|
|
2023
Q2 | $15.4M | Sell |
29,597
-344
| -1% | -$186K | 0.5% | 40 |
|
|
2023
Q1 | $17.3M | Buy |
29,941
+17,831
| +147% | +$10M | 0.58% | 31 |
|
|
2022
Q4 | $6.67M | Sell |
12,110
-437
| -3% | -$232K | 0.29% | 55 |
|
|
2022
Q3 | $6.36M | Buy |
12,547
+372
| +3% | +$208K | 0.29% | 60 |
|
|
2022
Q2 | $6.61M | Sell |
12,175
-67
| -0.5% | -$36.9K | 0.3% | 54 |
|
|
2022
Q1 | $7.29M | Sell |
12,242
-95
| -0.8% | -$54.6K | 0.29% | 59 |
|
|
2021
Q4 | $8.23M | Buy |
12,337
+499
| +4% | +$312K | 0.31% | 58 |
|
|
2021
Q3 | $6.76M | Buy |
11,838
+593
| +5% | +$325K | 0.27% | 65 |
|
|
2021
Q2 | $5.67M | Buy |
11,245
+57
| +0.5% | +$26.9K | 0.24% | 67 |
|
|
2021
Q1 | $5.11M | Buy |
11,188
+982
| +10% | +$469K | 0.24% | 75 |
|
|
2020
Q4 | $4.75M | Sell |
10,206
-276
| -3% | -$129K | 0.26% | 69 |
|
|
2020
Q3 | $4.63M | Buy |
10,482
+17
| +0.2% | +$7.02K | 0.29% | 60 |
|
|
2020
Q2 | $3.79M | Buy |
10,465
+278
| +3% | +$93.2K | 0.25% | 63 |
|
|
2020
Q1 | $2.89M | Sell |
10,187
-191
| -2% | -$60.2K | 0.23% | 67 |
|
|
2019
Q4 | $3.37M | Buy |
10,378
+416
| +4% | +$126K | 0.25% | 73 |
|
|
2019
Q3 | $2.9M | Buy |
9,962
+225
| +2% | +$64.4K | 0.25% | 72 |
|
|
2019
Q2 | $2.86M | Buy |
9,737
+321
| +3% | +$88.4K | 0.28% | 61 |
|
|
2019
Q1 | $2.58M | Buy |
9,416
+393
| +4% | +$97.8K | 0.29% | 64 |
|
|
2018
Q4 | $2.02M | Buy |
9,023
+969
| +12% | +$227K | 0.28% | 63 |
|
|
2018
Q3 | $1.97M | Buy |
8,054
+835
| +12% | +$192K | 0.24% | 72 |
|
|
2018
Q2 | $1.5M | Buy |
7,219
+359
| +5% | +$76.2K | 0.21% | 87 |
|
|
2018
Q1 | $1.42M | Buy |
6,860
+67
| +1% | +$14.1K | 0.22% | 86 |
|
|
2017
Q4 | $1.29M | Sell |
6,793
-135
| -2% | -$25.9K | 0.21% | 86 |
|
|
2017
Q3 | $1.3M | Sell |
6,928
-217
| -3% | -$39.3K | 0.22% | 86 |
|
|
2017
Q2 | $1.25M | Sell |
7,145
-66
| -0.9% | -$11.1K | 0.24% | 82 |
|
|
2017
Q1 | $1.21M | Sell |
7,211
-313
| -4% | -$47.8K | 0.24% | 80 |
|
|
2016
Q4 | $1.06M | Buy |
+7,524
| New | +$1.11M | 0.25% | 79 |
|
Other funds holding TMO
Parallel Advisors's TMO Position: Q2 2026 in Review
Parallel Advisors increased its Thermo Fisher Scientific (TMO) stake by 1.7% in Q2 2026, buying an estimated $309K and bringing the position to 37,694 shares worth $18.9M. The position accounts for 0.29% of the portfolio, ranked #57.
Parallel Advisors first reported a position in TMO in Q4 2016 and has held it in 39 quarters since. The position peaked at $20.8M in Q4 2025. 1,619 funds tracked by Wall St. Rank hold TMO as of Q2 2026.
- Parallel Advisors held 37,694 shares of Thermo Fisher Scientific worth $18.9M as of Q2 2026.
- Parallel Advisors bought 643 Thermo Fisher Scientific shares in Q2 2026, an estimated $309K.
- Thermo Fisher Scientific made up 0.29% of Parallel Advisors's portfolio in Q2 2026, its #57 holding.
- Parallel Advisors first reported a position in Thermo Fisher Scientific in Q4 2016 and has held it in 39 quarters since.
- Parallel Advisors's Thermo Fisher Scientific position peaked at $20.8M in Q4 2025.
- 1,619 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q2 2026.
Based on Parallel Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.